According to clinical guidelines, high-risk myeloma patients should receive intensified treatment regimens. However, heterogeneity in clinical markers and staging systems lead to various interpretations of...
Financing was co-led by EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund, as well as all existing investorsProceeds will support...
Support 6 Local Companies in Using AI Technology to Assist in Animation Production Showcases at Annecy Festival and Annecy International Animation Film Market (MIFA)...
Presentation to highlight updated six-month clinical results of a hypoimmune-modified primary pancreatic islet cell therapy for patients with type 1 diabetes
Presentation to highlight updated six-month clinical results of a hypoimmune-modified primary pancreatic islet cell therapy for patients with type 1 diabetes
-- Unprecedented data from FORTITUDE™ dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well...
I risultati dello studio di Fase 3 AMPLITUDE mettono in luce il potenziale di niraparib e abiraterone acetato nel ritardare la progressione del cancro e il peggioramento dei sintomi1